TREM2 and prostate adenocarcinoma: Among them, TREM2 was highly expressed in HNSC, COAD, uterine corpus endometrial carcinoma, LIHC, cholangiocarcinoma (CHOL), stomach adenocarcinoma (STAD), prostate adenocarcinoma (PRAD), kidney renal clear cell carcinoma (KIRC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), CESC, thyroid carcinoma (THCA), kidney chromophobe (KICH), GBM, and esophageal carcinoma (ESCA).